Updated Sept 03, 2026, 12:47 pm EDT / Original Sept 03, 2026, 11:10 am EDT
Moderna
MRNA
-2.23%
has received its second Sell rating on Wall Street, but the downgrade has little to do with the drugmaker’s commercial potential or pipeline prospects.
MRNA
-2.23%
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

#sept #moderna #sell #street